This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Cronos Group (CRON), Savara (SVRA) and Alkermes (ALKS)

Tipranks - Tipranks - Wed May 13, 7:40AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cronos Group (CRON), Savara (SVRA) and Alkermes (ALKS).

Claim 55% Off TipRanks

Cronos Group (CRON)

In a report released today, Nadine Sarwat from Bernstein assigned a Hold rating to Cronos Group. The company’s shares closed last Monday at $2.75.

According to TipRanks.com, Sarwat is a 1-star analyst with an average return of -3.3% and a 39.2% success rate. Sarwat covers the Consumer Goods sector, focusing on stocks such as Becle Sab De Cv, Brown-Forman B, and Molson Coors. ;'>

Currently, the analyst consensus on Cronos Group is a Moderate Buy with an average price target of $3.29.

See today’s best-performing stocks on TipRanks >>

Savara (SVRA)

LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Savara today and set a price target of $9.00. The company’s shares closed last Monday at $5.12, close to its 52-week high of $5.34.

According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 1.9% and a 40.5% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Centessa Pharmaceuticals, and Aquestive Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Savara with a $11.00 average price target, implying an 111.1% upside from current levels. In a report issued on May 5, Piper Sandler also maintained a Buy rating on the stock with a $16.00 price target.

Alkermes (ALKS)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Alkermes today and set a price target of $53.00. The company’s shares closed last Monday at $35.47, close to its 52-week high of $36.45.

According to TipRanks.com, Ear is a 3-star analyst with an average return of 2.2% and a 42.4% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Cartesian Therapeutics. ;'>

Currently, the analyst consensus on Alkermes is a Strong Buy with an average price target of $45.45, a 29.0% upside from current levels. In a report issued on May 5, TipRanks – OpenAI also upgraded the stock to Buy with a $38.00 price target.

Read More on CRON:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).